Adults who switched from Wegovy or Zepbound injections to a daily Foundayo (orforglipron) pill kept most of their weight loss over the next year. Former Wegovy users kept 79.3% of their earlier weight loss on orforglipron, regaining about 1 kg (2.2 lbs) on average, compared with 37.6% kept on placebo. Former Zepbound users kept 74.7%, regaining about 5 kg (11 lbs) on average, compared with 49.2% on placebo.
The findings come from ATTAIN-MAINTAIN, a phase 3b, double-blind, randomized trial published in Nature Medicine in May 2026. The trial tested whether a once-daily orforglipron pill can maintain weight loss after injectable GLP-1 treatment ends.
Key Points
- Trial: ATTAIN-MAINTAIN, a double-blind, randomized phase 3b trial of daily orforglipron vs placebo for weight-loss maintenance.
- Participants: 376 adults who had finished 72 weeks on Wegovy (semaglutide) or Zepbound (tirzepatide) in the SURMOUNT-5 trial, had lost at least 5% of body weight, and had reached a weight plateau.
- After Wegovy: Orforglipron kept 79.3% of earlier weight loss vs 37.6% on placebo, a difference of 41.7 percentage points. Average regain was about 1 kg (2.2 lbs).
- After Zepbound: Orforglipron kept 74.7% of earlier weight loss vs 49.2% on placebo, a difference of 25.5 percentage points. Average regain was about 5 kg (11 lbs).
- Follow-up: 52 weeks on the pill or placebo. No group stayed on the injection, so the trial cannot show whether switching matches continuing injections.
How the Trial Worked
Every participant came from SURMOUNT-5, the 72-week head-to-head trial of Zepbound (tirzepatide) against Wegovy (semaglutide). All 376 had lost at least 5% of their body weight and had plateaued. They were then randomly assigned to daily orforglipron or a daily placebo pill for 52 weeks: 205 former tirzepatide users and 171 former semaglutide users.
The design answers a narrow question: after stopping an injectable, does a daily pill preserve more weight loss than stopping treatment entirely. The placebo group shows what happens on no active drug. Because no group continued Wegovy or Zepbound, the trial does not compare switching with staying on the injection.
The Results by Prior Drug
Among former semaglutide users, the orforglipron group maintained 79.3% of their weight loss at 52 weeks, compared with 37.6% on placebo — a difference of 41.7 percentage points (95% CI 24.4–59.0; p < 0.001). Average regain in the orforglipron group was about 0.9 kg, or 2.2 lbs.
Among former tirzepatide users, the orforglipron group maintained 74.7% of their weight loss, compared with 49.2% on placebo — a difference of 25.5 percentage points (95% CI 14.5–36.5; p < 0.001). Average regain in the orforglipron group was about 5.0 kg, or 11 lbs.
Former tirzepatide users regained more than former semaglutide users. The researchers had expected that result in advance: tirzepatide acts on two gut-hormone targets (GIP and GLP-1) while orforglipron acts on one (GLP-1), so moving from tirzepatide to orforglipron is a step down in drug action. The gap between the two groups was smaller than that reasoning alone might predict, and the pill still preserved about three quarters of the loss after the tougher switch.
The weekly GLP-1 email
Plain-English answers on side effects, eating, cost and the newest medications. Free, one email a week.
How This Fits the Foundayo vs Wegovy Picture
Our Foundayo vs Wegovy comparison covers the two drugs as starting treatments: Foundayo is a once-daily pill with no food or water rules, while Wegovy comes as a weekly injection or a daily pill with strict morning dosing rules. In separate trials, Foundayo showed about 11% average weight loss over 72 weeks in ATTAIN-1, and standard Wegovy showed about 15% in its own trials. Those were different studies, not a head-to-head comparison.
ATTAIN-MAINTAIN adds the maintenance angle. It shows that switching from a Wegovy injection to a Foundayo pill preserves most of the loss, far more than stopping treatment. It does not show that the pill matches staying on the injection, and it does not compare the pill with the Wegovy pill as a maintenance option.
Foundayo's label has no switching instructions, so any switch from an injection to Foundayo is a prescriber decision. A prescriber sets the plan, including dose and timing. See our switching GLP-1 medications guide for general context on changing GLP-1 treatments.
Limits of the Study
The trial lasted one year, so maintenance past 52 weeks is unknown. No group stayed on Wegovy or Zepbound, so the trial cannot say whether switching to the pill is as good as continuing the injection. The doses used in the trial were development doses (12, 24, and 36 mg) that differ from Foundayo's marketed tablet strengths. Side effects were predominantly mild-to-moderate gastrointestinal events, in line with the GLP-1 class. The trial was funded by Eli Lilly, the maker of Foundayo, and the participants had all plateaued after 72 weeks in SURMOUNT-5, so the results apply to people in that situation rather than to everyone stopping an injectable.
Bottom Line
In ATTAIN-MAINTAIN, adults who switched from Wegovy or Zepbound injections to a daily orforglipron pill kept 79.3% and 74.7% of their earlier weight loss after a year, compared with 37.6% and 49.2% on placebo. Switching to the pill preserved most of the loss and beat stopping treatment by a wide margin, with more regain after Zepbound than after Wegovy. The trial does not show how switching compares with staying on the injection, or how maintenance holds up past one year.
This article summarizes published trial results for information only. It is not medical advice. Talk to your prescriber before changing, stopping, or switching any GLP-1 medication.
Sources
- Aronne LJ, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nature Medicine. 2026;32(7):2679–2687. Published online May 2026. ClinicalTrials.gov: NCT06584916.
- Oral GLP-1 medication helps patients maintain weight loss — Cornell Chronicle (Weill Cornell Medicine), May 13, 2026




